Characteristics of patients at enrolment into SLICC–RAS
| No of patients | 1494 |
| Age, years (mean (SD)) | 35.2 (13.4) |
| Gender (%) | |
| Female | 1336 (89.4) |
| Male | 158 (10.6) |
| Ethnicity (%) | |
| Caucasian | 660/1492 (44.2) |
| Black African/Afro-Caribbean | 228/1492 (15.3) |
| SE Asian | 303/1492 (20.3) |
| Hispanic | 240/1492 (16.1) |
| Other | 61/1492 (4.1) |
| Region (%) | |
| Canada | 358/1477 (24.2) |
| Mexico | 194/1477 (13.1) |
| USA | 374/1477 (25.3) |
| Asia | 168/1477 (11.4) |
| Europe | 383/1477 (25.3) |
| CHD risk factors (mean (SD)) | |
| BP systolic, mm Hg | 119.5 (16.8) |
| BP diastolic, mm Hg | 75.3 (11.0) |
| On AHT medication, % | 435 (29.1) |
| Total cholesterol, mmol/l | 4.93 (1.49) |
| Triglyceride, mmol/l | 1.79 (1.19) |
| HDL-cholesterol, mmol/l | 1.39 (0.60) |
| On lipid-lowering medication, % | 171 (11.5) |
| Glucose, mmol/l | 5.03 (1.63) |
| Diabetes, % | 50 (3.4) |
| Smoker current, % | 225 (15.1) |
| Premenopausal, % | 1244 (83.3) |
| BMI | 25.1 (5.9) |
| WC, cm | 82.9 (14.0) |
| 5-Year % Framingham risk | |
| Women | 0.57 |
| Men | 5.03 |
| Disease duration, weeks (mean SD) | 24.1 (18.0) |
| SLEDAI (mean SD) | 5.5 (5.4) |
| SLICC/ACR-DI=0 | 528 (81.9%) |
| Disease phenotype (%) | |
| Active renal disease | 314 (22.9) |
| Anti-dsDNA positive | 541/1347 (40.2) |
| Low complement | 519/1349 (38.5) |
| Thrombocytopenia | 44/1313 (3.4) |
| Oral CS use (median (IQR)) | 1043 (69.8) |
| Average CS dose, mg | 20 (10, 30) |
| Highest CS dose, mg | 40 (20, 60) |
| Cumulative CS dose, g | 2.6 (1.1, 5.0) |
| Pulse IV CS (%) | 70/1423 (4.9) |
| Immunosuppressant use (%) | 599/1491 (31.0) |
| Azathioprine | 262 (43.7) |
| Methotrexate | 104 (17.4) |
| Mycophenolate mofetil | 98 (16.4) |
| IV cyclophosphamide | 95 (15.9) |
| Ciclosporin | 21 (3.5) |
| Other | 19 (3.2) |
| Antimalarial use (%) | 971 (65.0) |
ACR, American College of Rheumatology; AHT, antihypertensive; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CS, corticosteroid; DI, damage index; HDL, high-density lipoprotein; IV, intravenous; RAS, Registry for Atherosclerosis; SLEDAI, systemic lupus erythematosus disease activity index; SLICC, Systemic Lupus International Collaborating Clinics; WC, waist circumference.